UroGen Pharma URGN Restricted Investments, Noncurrent
Restricted Investments, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedInvestmentsNoncurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's restricted investments, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's restricted investments, noncurrent?
- UroGen Pharma (URGN) reported restricted investments, noncurrent of $177K in Q1 2026.
- How has UroGen Pharma's restricted investments, noncurrent changed year-over-year?
- UroGen Pharma's restricted investments, noncurrent increased by 0.6% year-over-year, from $176K to $177K.
- What is the long-term trend for UroGen Pharma's restricted investments, noncurrent?
- Over 5 years (2020 to 2025), UroGen Pharma's restricted investments, noncurrent has grown at a -4.5% compound annual growth rate (CAGR), from $223K to $177K.
- What does restricted investments, noncurrent mean?
- This represents cash or investment assets that are legally or contractually restricted from being used for general corporate purposes for a period exceeding one year. These assets are typically held as collateral for long-term debt, lease agreements, or specific regulatory requirements. Monitoring this balance helps investors understand the portion of the company's long-term liquidity that is unavailable for operational investment or debt repayment.